Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinson's Disease Target LRRK2
LA JOLLA, Calif., Dec. 16, 2010 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S (Lundbeck) utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
"We are pleased that our expertise in protein expression, purification and crystallization has been recognized by a leader in CNS drug discovery and look forward to a long and productive relationship with Lundbeck," says Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.
"Zenobia has a strong structural biology team and the lead on this important Parkinson's target. We are pleased to be working with them," says Klaus Baek Simonsen, Head of Discovery Chemistry at H. Lundbeck A/S.
Under the agreement, Zenobia will complete x-ray crystal structures of wild-type and the Parkinson's disease-associated mutant, G2019S, in complex with Lundbeck lead compounds. Zenobia retains all rights and ownership of the LRRK2 structure and to their internal LRRK2 chemistry program.
About Zenobia
Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's disease and pediatric neuroblastoma.
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.
SOURCE Zenobia Therapeutics, Inc.
Share this article